Nonalcoholic fatty liver disease and polycystic ovary syndrome

World Journal of Gastroenterology

Volumn , Issue 26, 2014, Pages 8351-8363

  Vassilatou, Evangeline ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Hyperandrogenism; Insulin resistance; Nonalcoholic fatty liver disease; Obesity; Polycystic ovary syndrome; Premenopausal women

Indexed keywords

AMINOTRANSFERASE; INSULIN; METFORMIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ANTIDIABETIC AGENT;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DISEASE COURSE; EXERCISE; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER DISEASE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PREVALENCE; RISK FACTOR; WEIGHT REDUCTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL STUDY; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; GENETIC LINKAGE; LABORATORY TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTON NUCLEAR MAGNETIC RESONANCE; ANIMAL; CALORIC RESTRICTION; COMORBIDITY; FEMALE; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY, ABDOMINAL; POLYCYSTIC OVARY SYNDROME; RISK ASSESSMENT; RISK REDUCTION; TREATMENT OUTCOME;

ADIPOSITY; ANIMALS; CALORIC RESTRICTION; COMORBIDITY; EXERCISE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METFORMIN; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY, ABDOMINAL; POLYCYSTIC OVARY SYNDROME; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84904395452     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i26.8351     Document Type: Article

References (107)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231 [PMID: 11961152]
2. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419 [PMID: 10348825] (Pubitemid 29258890)
3. Clark JM . The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006; 40 Suppl 1: S5-10 [PMID: 16540768]
4. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-140 [PMID: 12105842] (Pubitemid 34747534)
5. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-455 [PMID: 10569299] (Pubitemid 29528333)
6. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, Ponti V, Pagano G, Ferrannini E, Rizzetto M. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005; 48: 634-642 [PMID: 15747110 DOI: 10.1007/s00125-005-1682-x] (Pubitemid 40591217)
7. Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 27-38 [PMID: 17690317]
8. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999; 84: 4006-4011 [PMID: 10566641 DOI: 10.1210/jc.84.11.4006] (Pubitemid 30644187)
9. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010; 25: 544-551 [PMID: 19910321 DOI: 10.1093/humrep/dep399]
10. Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980; 50: 113-116 [PMID: 7350174] (Pubitemid 10203585)
11. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165-1174 [PMID: 2670645] (Pubitemid 19250404)
12. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999; 84: 165-169 [PMID: 9920077] (Pubitemid 29036695)
13. Carmina E, Bucchieri S, Esposito A, Del Puente A, Mansueto P, Orio F, Di Fede G, Rini G. Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab 2007; 92: 2500-2505 [PMID: 17405838] (Pubitemid 47037349)
14. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001; 111: 607-613 [PMID: 11755503] (Pubitemid 34088070)
15. Essah PA, Nestler JE. The metabolic syndrome in polycystic ovary syndrome. J Endocrinol Invest 2006; 29: 270-280 [PMID: 16682845]
16. Zelman S. The liver in obesity. AMA Arch Intern Med 1952; 90: 141-156 [PMID: 14943295]
17. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-438 [PMID: 7382552] (Pubitemid 10057164)
18. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-669 [PMID: 10051466] (Pubitemid 29109578)
19. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003; 124: 71-79 [PMID: 12512031] (Pubitemid 36055340)
20. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98: 960-967 [PMID: 12809815] (Pubitemid 36733754)
21. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988; 27: 142-149 [PMID: 3047469]
22. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52 [PMID: 15895401] (Pubitemid 40911310)
23. Garcia Ureña MA, Colina Ruiz-Delgado F, Moreno González E, Jiménez Romero C, García García I, Loinzaz Segurola C, Gonzalez-Pinto R. Hepatic steatosis in liver transplant donors: common feature of donor population? World J Surg 1998; 22: 837-844 [PMID: 9673556] (Pubitemid 28322081)
24. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH, Dobbins RL. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005; 288: E462-E468 [PMID: 15339742 DOI: 10.1152/ajpendo.00064.2004] (Pubitemid 40110657)
25. Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006; 45: 600-606 [PMID: 16899321 DOI: 10.1016/j.jhep.2006.06.013] (Pubitemid 44307393)
26. Silverman JF, Pories WJ, Caro JF. Liver pathology in diabetes mellitus and morbid obesity. Clinical, pathological, and biochemical considerations. Pathol Annu 1989; 24 Pt 1: 275-302 [PMID: 2654841]
27. Akbar DH, Kawther AH. Nonalcoholic fatty liver disease in Saudi type 2 diabetic subjects attending a medical outpatient clinic: prevalence and general characteristics. Diabetes Care 2003; 26: 3351-3352 [PMID: 14633828] (Pubitemid 37466902)
28. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-379 [PMID: 11826411 DOI: 10.1053/jhep.2001.30692] (Pubitemid 34106377)
29. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-1192 [PMID: 11266382] (Pubitemid 32246672)
30. Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM, Goto T, Westerbacka J, Sovijärvi A, Halavaara J, Yki-Järvinen H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87: 3023-3028 [PMID: 12107194] (Pubitemid 34816338)
31. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-887 [PMID: 17167477] (Pubitemid 46024995)
32. Tamura S, Shimomura I. Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1139-1142 [PMID: 15864343] (Pubitemid 40629030)
33. Wolfrum C, Asilmaz E, Luca E, Friedman JM, Stoffel M. Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. Nature 2004; 432: 1027-1032 [PMID: 15616563] (Pubitemid 40052233)
34. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of nonalcoholic steatohepatitis. Trends Mol Med 2008; 14: 72-81 [PMID: 18218340 DOI: 10.1016/j.molmed.2007.12.003]
35. Utzschneider KM, Kahn SE. Review: The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006; 91: 4753-4761 [PMID: 16968800 DOI: 10.1210/jc.2006-0587] (Pubitemid 44917301)
36. Stefan N, Kantartzis K, Häring HU. Causes and metabolic consequences of Fatty liver. Endocr Rev 2008; 29: 939-960 [PMID: 18723451 DOI: 10.1210/er.2008-0009]
37. Hocking S, Samocha-Bonet D, Milner KL, Greenfield JR, Chisholm DJ. Adiposity and insulin resistance in humans: the role of the different tissue and cellular lipid depots. Endocr Rev 2013; 34: 463-500 [PMID: 23550081 DOI: 10.1210/er.2012-1041]
38. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-1350 [PMID: 20879883 DOI: 10.1056/NEJMra0912063]
39. Stein I, Leventhal M. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29: 181-191
40. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-47 [PMID: 14688154 DOI: 10.1093/humrep/deh098]
41. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006; 91: 4237-4245 [PMID: 16940456 DOI: 10.1210/jc.2006-0178] (Pubitemid 44833391)
42. Kahn CR, Flier JS, Bar RS, Archer JA, Gorden P, Martin MM, Roth J. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med 1976; 294: 739-745 [PMID: 176581]
43. Pasquali R, Venturoli S, Paradisi R, Capelli M, Parenti M, Melchionda N. Insulin and C-peptide levels in obese patients with polycystic ovaries. Horm Metab Res 1982; 14: 284-287 [PMID: 6749626] (Pubitemid 12075396)
44. Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1983; 57: 356-359 [PMID: 6223044] (Pubitemid 13032489)
45. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 1987; 65: 499-507 [PMID: 3305551] (Pubitemid 17131438)
46. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992; 41: 1257-1266 [PMID: 1397698]
47. Pasquali R, Casimirri F, Venturoli S, Antonio M, Morselli L, Reho S, Pezzoli A, Paradisi R. Body fat distribution has weight-independent effects on clinical, hormonal, and metabolic features of women with polycystic ovary syndrome. Metabolism 1994; 43: 706-713 [PMID: 8201958] (Pubitemid 24181196)
48. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22: 141-146 [PMID: 10333916 DOI: 10.2337/diacare.22.1.141] (Pubitemid 29028311)
49. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 2012; 33: 981-1030 [PMID: 23065822 DOI: 10.1210/er.2011-1034]
50. Huang G, Coviello A. Clinical update on screening, diagnosis and management of metabolic disorders and cardiovascular risk factors associated with polycystic ovary syndrome. Curr Opin Endocrinol Diabetes Obes 2012; 19: 512-519 [PMID: 23108199 DOI: 10.1097/MED.0b013e32835a000e]
51. Dawson AJ, Sathyapalan T, Smithson JA, Vince RV, Coady AM, Ajjan R, Kilpatrick ES, Atkin SL. A comparison of cardiovascular risk indices in patients with polycystic ovary syndrome with and without coexisting nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 2014; 80: 843-849 [PMID: 23746214 DOI: 10.1111/cen.12258]
52. Toulis KA, Goulis DG, Mintziori G, Kintiraki E, Eukarpidis E, Mouratoglou SA, Pavlaki A, Stergianos S, Poulasouchidou M, Tzellos TG, Makedos A, Chourdakis M, Tarlatzis BC. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update 2011; 17: 741-760 [PMID: 21628302 DOI: 10.1093/humupd/dmr025]
53. Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, Baron AD. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001; 103: 1410-1415 [PMID: 11245645 DOI: 10.1161/01.CIR.103.10.1410] (Pubitemid 32220633)
54. Vryonidou A, Papatheodorou A, Tavridou A, Terzi T, Loi V, Vatalas IA, Batakis N, Phenekos C, Dionyssiou-Asteriou A. Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 2740-2746 [PMID: 15741256 DOI: 10.1210/jc.2004-2363] (Pubitemid 40686318)
55. Sprung VS, Jones H, Pugh CJ, Aziz NF, Daousi C, Kemp GJ, Green DJ, Cable NT, Cuthbertson DJ. Endothelial dysfunction in hyperandrogenic polycystic ovary syndrome is not explained by either obesity or ectopic fat deposition. Clin Sci (Lond) 2014; 126: 67-74 [PMID: 23826984 DOI: 10.1042/CS20130186]
56. Randeva HS, Tan BK, Weickert MO, Lois K, Nestler JE, Sattar N, Lehnert H. Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev 2012; 33: 812-841 [PMID: 22829562 DOI: 10.1210/er.2012-1003]
57. Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum Fertil (Camb) 2000; 3: 101-105 [PMID: 11844363]
58. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at longterm follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000; 52: 595-600 [PMID: 10792339] (Pubitemid 30337085)
59. Schmidt J, Landin-Wilhelmsen K, Brännström M, Dahlgren E. Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled follow-up study. J Clin Endocrinol Metab 2011; 96: 3794-3803 [PMID: 21956415 DOI: 10.1210/jc.2011-1677]
60. Solomon CG, Hu FB, Dunaif A, Rich-Edwards JE, Stampfer MJ, Willett WC, Speizer FE, Manson JE. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002; 87: 2013-2017 [PMID: 11994334] (Pubitemid 34521483)
61. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, Cooper-Dehoff RM, Johnson BD, Vaccarino V, Reis SE, Bittner V, Hodgson TK, Rogers W, Pepine CJ. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health - National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008; 93: 1276-1284 [PMID: 18182456 DOI: 10.1210/jc.2007-0425] (Pubitemid 351519721)
62. Krentz AJ, von Mühlen D, Barrett-Connor E. Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease. Menopause 2007; 14: 284-292 [PMID: 17245231] (Pubitemid 46673480)
63. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, Lobo R, Norman RJ, Talbott E, Dumesic DA. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AEPCOS) Society. J Clin Endocrinol Metab 2010; 95: 2038-2049 [PMID: 20375205 DOI: 10.1210/jc.2009-2724]
64. Franks S, Gilling-Smith C, Watson H, Willis D. Insulin action in the normal and polycystic ovary. Endocrinol Metab Clin North Am 1999; 28: 361-378 [PMID: 10352923] (Pubitemid 29242718)
65. Brown AJ, Tendler DA, McMurray RG, Setji TL. Polycystic ovary syndrome and severe nonalcoholic steatohepatitis: beneficial effect of modest weight loss and exercise on liver biopsy findings. Endocr Pract 2005; 11: 319-324 [PMID: 16191492]
66. Adams LA, Talwalkar JA. Diagnostic evaluation of nonalcoholic fatty liver disease. J Clin Gastroenterol 2006; 40 Suppl 1: S34-S38 [PMID: 16540765] (Pubitemid 44309541)
67. Schwimmer JB, Khorram O, Chiu V, Schwimmer WB. Abnormal aminotransferase activity in women with polycystic ovary syndrome. Fertil Steril 2005; 83: 494-497 [PMID: 15705403] (Pubitemid 40221817)
68. Setji TL, Holland ND, Sanders LL, Pereira KC, Diehl AM, Brown AJ. Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 1741-1747 [PMID: 16492691 DOI: 10.1210/jc.2005-2774]
69. Barfield E, Liu YH, Kessler M, Pawelczak M, David R, Shah B. The prevalence of abnormal liver enzymes and metabolic syndrome in obese adolescent females with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2009; 22: 318-322 [PMID: 19576817 DOI: 10.1016/j.jpag.2009.03.003]
70. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L, Zanuso F, Mozzi F, Milani S, Conte D, Colombo M, Sirchia G. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10 [PMID: 12093239]
71. Gangale MF, Miele L, Lanzone A, Sagnella F, Martinez D, Tropea A, Moro F, Morciano A, Ciardulli A, Palla C, Pompili M, Cefalo C, Grieco A, Apa R. Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperin-sulinaemic overweight patients with polycystic ovarian syndrome. Clin Endocrinol (Oxf) 2011; 75: 520-527 [PMID: 21569072 DOI: 10.1111/j.1365-2265.2011.04093.x]
72. Cerda C, Pérez-Ayuso RM, Riquelme A, Soza A, Villaseca P, Sir-Petermann T, Espinoza M, Pizarro M, Solis N, Miquel JF, Arrese M. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol 2007; 47: 412-417 [PMID: 17560682 DOI: 10.1016/j.jhep.2007.04.012] (Pubitemid 47176161)
73. Vassilatou E, Lafoyianni S, Vryonidou A, Ioannidis D, Kosma L, Katsoulis K, Papavassiliou E, Tzavara I. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod 2010; 25: 212-220 [PMID: 19887498 DOI: 10.1093/humrep/dep380]
74. Economou F, Xyrafis X, Livadas S, Androulakis II, Argyrakopoulou G, Christakou CD, Kandaraki E, Palioura E, Diamanti-Kandarakis E. In overweight/obese but not in normal-weight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls. Hormones (Athens) 2009; 8: 199-206 [PMID: 19671519]
75. Markou A, Androulakis II, Mourmouris C, Tsikkini A, Samara C, Sougioultzis S, Piaditis G, Kaltsas G. Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome. Fertil Steril 2010; 93: 1220-1226 [PMID: 19171337 DOI: 10.1016/j.fertnstert.2008.12.008]
76. Chen MJ, Chiu HM, Chen CL, Yang WS, Yang YS, Ho HN. Hyperandrogenemia is independently associated with elevated alanine aminotransferase activity in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2010; 95: 3332-3341 [PMID: 20427499 DOI: 10.1210/jc.2009-2698]
77. Lerchbaum E, Gruber HJ, Schwetz V, Giuliani A, Möller R, Pieber TR, Obermayer-Pietsch B. Fatty liver index in polycystic ovary syndrome. Eur J Endocrinol 2011; 165: 935-943 [PMID: 21937505 DOI: 10.1530/EJE-11-0614]
78. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009; 50: 1072-1078 [PMID: 19585618 DOI: 10.1002/hep.23050]
79. Tan S, Bechmann LP, Benson S, Dietz T, Eichner S, Hahn S, Janssen OE, Lahner H, Gerken G, Mann K, Canbay A. Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. J Clin Endocrinol Metab 2010; 95: 343-348 [PMID: 19906783 DOI: 10.1210/jc.2009-1834]
80. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33 [PMID: 17081293 DOI: 10.1186/1471-230X-6-33]
81. Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T, Kato T, Takeda N, Okuda J, Ida K, Kawahito Y, Yoshikawa T, Okanoue T. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007; 102: 2708-2715 [PMID: 17894848] (Pubitemid 350179336)
82. Ballestri S, Lonardo A, Romagnoli D, Carulli L, Losi L, Day CP, Loria P. Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. Liver Int 2012; 32: 1242-1252 [PMID: 22520641 DOI: 10.1111/j.1478-3231.2012.02804.x]
83. Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh HC, Futterweit W. Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol 2007; 5: 496-501 [PMID: 17287148 DOI: 10.1016/j.cgh.2006.10.010] (Pubitemid 46575354)
84. Ma RC, Liu KH, Lam PM, Cheung LP, Tam WH, Ko GT, Chan MH, Ho CS, Lam CW, Chu WC, Tong PC, So WY, Chan JC, Chow CC. Sonographic measurement of mesenteric fat predicts presence of fatty liver among subjects with polycystic ovary syndrome. J Clin Endocrinol Metab 2011; 96: 799-807 [PMID: 21190980 DOI: 10.1210/jc.2010-1608]
85. Zueff LF, Martins WP, Vieira CS, Ferriani RA. Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome. Ultrasound Obstet Gynecol 2012; 39: 341-347 [PMID: 21898634 DOI: 10.1002/uog.10084]
86. Borruel S, Fernández-Durán E, Alpañés M, Martí D, Alvarez-Blasco F, Luque-Ramírez M, Escobar-Morreale HF. Global adiposity and thickness of intraperitoneal and mesenteric adipose tissue depots are increased in women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 2013; 98: 1254-1263 [PMID: 23386652 DOI: 10.1210/jc.2012-3698]
87. Michaliszyn SF, Lee S, Tfayli H, Arslanian S. Polycystic ovary syndrome and nonalcoholic fatty liver in obese adolescents: association with metabolic risk profile. Fertil Steril 2013; 100: 1745-1751 [PMID: 24034940 DOI: 10.1016/j.fertnstert.2013.08.015]
88. Cussons AJ, Watts GF, Mori TA, Stuckey BG. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metab 2009; 94: 3842-3848 [PMID: 19622617 DOI: 10.1210/jc.2009-0870]
89. Jones H, Sprung VS, Pugh CJ, Daousi C, Irwin A, Aziz N, Adams VL, Thomas EL, Bell JD, Kemp GJ, Cuthbertson DJ. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab 2012; 97: 3709-3716 [PMID: 22837189 DOI: 10.1210/jc.2012-1382]
90. Carmina E . Need for liver evaluation in polycystic ovary syndrome. J Hepatol 2007; 47: 313-315 [PMID: 17624467 DOI: 10.1016/j.jhep.2007.06.009] (Pubitemid 47176169)
91. Brzozowska MM, Ostapowicz G, Weltman MD. An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome. J Gastroenterol Hepatol 2009; 24: 243-247 [PMID: 19215335 DOI: 10.1111/j.1440-1746.2008.05740.x]
92. Hamaguchi M, Kojima T, Ohbora A, Takeda N, Fukui M, Kato T. Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women. World J Gastroenterol 2012; 18: 237-243 [PMID: 22294826 DOI: 10.3748/wjg.v18.i3.237]
93. Targher G, Solagna E, Tosi F, Castello R, Spiazzi G, Zoppini G, Muggeo M, Day CP, Moghetti P. Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome. J Endocrinol Invest 2009; 32: 695-700 [PMID: 19542757 DOI: 10.3275/6375]
94. Preiss D, Sattar N, Harborne L, Norman J, Fleming R. The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome. Int J Clin Pract 2008; 62: 1337-1343 [PMID: 18565127 DOI: 10.1111/j.1742-1241.2008.01825.x]
95. Kauffman RP, Baker TE, Baker V, Kauffman MM, Castracane VD. Endocrine factors associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome: do androgens play a role? Gynecol Endocrinol 2010; 26: 39-46 [PMID: 20001571 DOI: 10.3109/09513590903184084]
96. Baranova A, Tran TP, Afendy A, Wang L, Shamsaddini A, Mehta R, Chandhoke V, Birerdinc A, Younossi ZM. Molecular signature of adipose tissue in patients with both non-alcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome (PCOS). J Transl Med 2013; 11: 133 [PMID: 23721173 DOI: 10.1186/1479-5876-11-133]
97. Barber TM, Franks S. Genetics of polycystic ovary syndrome. Front Horm Res 2013; 40: 28-39 [PMID: 24002403 DOI: 10.1159/000341682]
98. Baranova A, Tran TP, Birerdinc A, Younossi ZM. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011; 33: 801-814 [PMID: 21251033 DOI: 10.1111/j.1365-2036.2011.04579.x]
99. Chen ZJ, Zhao H, He L, Shi Y, Qin Y, Shi Y, Li Z, You L, Zhao J, Liu J, Liang X, Zhao X, Zhao J, Sun Y, Zhang B, Jiang H, Zhao D, Bian Y, Gao X, Geng L, Li Y, Zhu D, Sun X, Xu JE, Hao C, Ren CE, Zhang Y, Chen S, Zhang W, Yang A, Yan J, Li Y, Ma J, Zhao Y. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet 2011; 43: 55-59 [PMID: 21151128 DOI: 10.1038/ng.732]
100. Goodarzi MO, Jones MR, Li X, Chua AK, Garcia OA, Chen YD, Krauss RM, Rotter JI, Ankener W, Legro RS, Azziz R, Strauss JF, Dunaif A, Urbanek M. Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts. J Med Genet 2012; 49: 90-95 [PMID: 22180642 DOI: 10.1136/jmedgenet-2011-100427]
101. Welt CK, Styrkarsdottir U, Ehrmann DA, Thorleifsson G, Arason G, Gudmundsson JA, Ober C, Rosenfield RL, Saxena R, Thorsteinsdottir U, Crowley WF, Stefansson K. Variants in DENND1A are associated with polycystic ovary syndrome in women of European ancestry. J Clin Endocrinol Metab 2012; 97: E1342-E1347 [PMID: 22547425 DOI: 10.1210/jc.2011-3478]
102. Day CP. Genetic and environmental susceptibility to non-alcoholic fatty liver disease. Dig Dis 2010; 28: 255-260 [PMID: 20460920 DOI: 10.1159/000282098]
103. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461-1465 [PMID: 18820647 DOI: 10.1038/ng.257]
104. Dongiovanni P, Donati B, Fares R, Lombardi R, Mancina RM, Romeo S, Valenti L. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol 2013; 19: 6969-6978 [PMID: 24222941]
105. Hossain N, Stepanova M, Afendy A, Nader F, Younossi Y, Rafiq N, Goodman Z, Younossi ZM. Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS). Scand J Gastroenterol 2011; 46: 479-484 [PMID: 21114431 DOI: 10.3109/00365521.2010.539251]
106. Nascimbeni F, Ballestri S, Di Tommaso L, Piccoli M, Lonardo A. Inflammatory hepatocellular adenomatosis, metabolic syndrome, polycystic ovary syndrome and non-alcoholic steatohepatitis: chance tetrad or association by necessity? Dig Liver Dis 2014; 46: 288-289 [PMID: 24183950]
107. Dunaif A. Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome - a reappraisal. Nat Clin Pract Endocrinol Metab 2008; 4: 272-283 [PMID: 18364705 DOI: 10.1038/ncpendmet0787] (Pubitemid 351571139)